ITMCTR2100005445
Not yet recruiting
Phase 1
Exploratory Research on the Efficacy Evaluation of Electroacupuncture in the Treatment of Cerebral Apoplexy and Paralysis Stage Based on the Theory of Treating Flaccid Paralysis by Yangming A
ConditionsStroke
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Stroke
- Sponsor
- Huashan Hospital,Fudan University
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.For the patients who met the diagnostic criteria for ischemic stroke (with reference to the 2019 edition of Chinese diagnostic criteria for cerebrovascular diseases) and were confirmed as ischemic stroke by CT or MRI, the lesion suggested that the type was hemiplegia due to unilateral hemispheric injury;
- •2\.The patient suffers from the first stroke, and the condition is basically stable with no conscious disorder;
- •3\.Upper limb Brunnstrom grade 1; Ashworth upper extremity score: 0;
- •4\.Vital signs are stable;
- •5\.Aged between 45\-75 years old; No gender limitation;
- •6\.The patient or his/her immediate family members and spouse sign the informed consent form.
Exclusion Criteria
- •1\.There are diseases or conditions that seriously affect patients' activities, such as important organ failure or critical condition, and cancer;
- •2\.Patients combined with systemic infection, or the condition is seriously unstable;
- •3\.Patients complicated with severe musculoskeletal diseases;
- •4\.Patients complicated with severe cognitive and mental diseases;
- •5\.Fear of acupuncture and dizziness;
- •6\.Patients with heart disease;
- •7\.The affected upper limb of the patient has metal implants, and the patient is allergic to EEG ointment;
- •8\.Pregnant and lactating women;
- •9\.Patients have participated in other clinical trials that affect the evaluation of the results of this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Clinical Trial for Prevention of Cisplatin-Induced Renal NephrotoxicityCancerJPRN-jRCTs041220021Kondo Masashi21
Recruiting
Not Applicable
Exploratory study of CLZ-BM3D in patients with peripheral occlusive arterial diseasePatients with peripheral occlusive arterial diseaseJPRN-jRCT2072220114akamura Masato24
Active, not recruiting
Phase 1
Reseach study that will evaluate the efficacy and safety of Bilastine in reducing itching in patients with chronic spontaneous urticaria and other skin diseases.Chronic spontaneous urticaria and the following skin disorders:1 - Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic dermatitis, nummular eczema, autosensitisation dermatitis, dyshidrotic eczema, asteatotic eczema, lichen simplex chronicus).2 - Prurigo (acute prurigo, subacute prurigo, chronic prurigo).3 - Cutaneous pruritus (systemic cutaneous pruritus, local cutaneous pruritus).MedDRA version: 19.0Level: HLTClassification code 10012435Term: Dermatitis and eczemaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 19.0Level: PTClassification code 10037083Term: PrurigoSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 19.0Level: PTClassification code 10052568Term: Urticaria chronicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2016-001505-17-ESFAES FARMA, S.A.115
Active, not recruiting
Phase 1
Reseach study that will evaluate the efficacy and safety of Bilastine in reducing itching in patients with chronic spontaneous urticaria and other skin diseases.EUCTR2016-001505-17-HUFAES FARMA, S.A.115
Active, not recruiting
Phase 1
The exploratory study of EFE in COVID-19 patientsCOVID-19JPRN-jRCT2031210063Odaguchi Hiroshi156